洗手液被苯污染。防曬霜和干洗發(fā)水也不例外。如今,廣泛使用的消費(fèi)品——痤瘡治療產(chǎn)品也被發(fā)現(xiàn)含有高濃度的致癌化學(xué)物質(zhì)。
3月5日的晚些時(shí)候,一家獨(dú)立檢測(cè)實(shí)驗(yàn)室在向美國(guó)食品與藥品監(jiān)督管理局(US Food and Drug Administration)提交的一份請(qǐng)?jiān)笗蟹Q,包括高倫雅芙(Proactiv)、塔吉特(Target Corp.)旗下的Up & Up和倩碧(Clinique)在內(nèi)的品牌的祛痘產(chǎn)品中含有高濃度的致癌物質(zhì)。該實(shí)驗(yàn)室要求美國(guó)食品與藥品監(jiān)督管理局在監(jiān)管機(jī)構(gòu)調(diào)查期間召回受污染的護(hù)理產(chǎn)品。這些產(chǎn)品都含有活性成分過(guò)氧化苯甲酰。
據(jù)美國(guó)疾病控制與預(yù)防中心(US Centers for Disease Control and Prevention)稱,苯是汽油和煙草煙霧的天然成分,如果吸入高濃度的苯,可能就會(huì)導(dǎo)致白血病。在過(guò)去的三年中,在幾種流行產(chǎn)品里檢測(cè)出苯,這提高了消費(fèi)者對(duì)浴室柜中潛在威脅的認(rèn)識(shí),也引發(fā)了人們質(zhì)疑美國(guó)食品與藥品監(jiān)督管理局對(duì)該行業(yè)監(jiān)管不力。包括強(qiáng)生公司(Johnson & Johnson)、聯(lián)合利華公司(Unilever Plc)和寶潔公司(Procter & Gamble Co.)在內(nèi)的公司已經(jīng)召回了產(chǎn)品。
總部位于美國(guó)康涅狄格州紐黑文的檢測(cè)實(shí)驗(yàn)室Valisure LLC于3月5日提交了請(qǐng)?jiān)笗?,并揭露了之前發(fā)現(xiàn)的風(fēng)險(xiǎn)。該公司將自身定位為消費(fèi)者的看門人。Valisure在產(chǎn)品研究方面聲名鵲起,并與包括凱撒醫(yī)療機(jī)構(gòu)(Kaiser Permanente)和美國(guó)國(guó)防部(US Department of Defense)在內(nèi)的大型醫(yī)療保健系統(tǒng)達(dá)成協(xié)議,對(duì)其成員使用的藥物進(jìn)行檢測(cè),以剔除不達(dá)標(biāo)的治療產(chǎn)品。
在痤瘡研究中,Valisure測(cè)試了66種過(guò)氧化苯甲酰產(chǎn)品,包括主要零售商柜臺(tái)或處方銷售的面霜、乳液、凝膠和洗劑。雖然根據(jù)美國(guó)食品與藥品監(jiān)督管理局的指南,允許苯的含量不超過(guò)百萬(wàn)分之二,但Valisure在一些治療產(chǎn)品里發(fā)現(xiàn)的苯含量高達(dá)這一標(biāo)準(zhǔn)的九倍。當(dāng)這些產(chǎn)品在更高的溫度下進(jìn)行測(cè)試時(shí),苯含量明顯升高,測(cè)試的目的是模擬產(chǎn)品隨著時(shí)間的推移可能發(fā)生分解的情況。例如,如果產(chǎn)品存放在蒸汽彌漫的浴室的藥柜中。
在Valisure的穩(wěn)定性測(cè)試中,由Taro Pharmaceutical Industries Ltd.生產(chǎn)的高倫雅芙2.5%過(guò)氧化苯甲酰面霜里的苯含量高達(dá)百萬(wàn)分之1,761,而塔吉特的一款類似面霜的苯含量高達(dá)百萬(wàn)分之1,598,雅詩(shī)蘭黛旗下倩碧的一款面霜的苯含量達(dá)到了百萬(wàn)分之401。利潔時(shí)集團(tuán)(Reckitt Benckiser Group Plc)生產(chǎn)的Clearasil的10%過(guò)氧化苯甲酰面霜最初的測(cè)試結(jié)果剛剛達(dá)到美國(guó)食品與藥品監(jiān)督管理局的限值,但在高溫下暴露兩周多后,苯含量躍升至百萬(wàn)分之308。
利潔時(shí)集團(tuán)在一份聲明中表示:“利潔時(shí)確信,所有Clearasil產(chǎn)品在按照標(biāo)簽說(shuō)明使用和儲(chǔ)存時(shí)都是安全的。”利潔時(shí)稱,公司的首要任務(wù)是保證產(chǎn)品的安全和質(zhì)量。該公司沒有回答是否檢測(cè)了其祛痘霜里的苯含量。
美國(guó)食品與藥品監(jiān)督管理局、Taro Pharmaceuticals和雅詩(shī)蘭黛的代表沒有回應(yīng)置評(píng)請(qǐng)求。塔吉特拒絕置評(píng)。倫敦股市收盤時(shí),利潔時(shí)股價(jià)下跌2%,聯(lián)合利華下跌0.4%;紐約股市收盤時(shí),雅詩(shī)蘭黛下跌1.3%,Taro Pharmaceuticals下跌2.4%。
據(jù)美國(guó)皮膚病學(xué)會(huì)(American Academy of Dermatology)稱,痤瘡是美國(guó)最常見的皮膚病,每年影響多達(dá)5,000萬(wàn)人。在青少年和年輕人中,這一數(shù)字甚至更高:12歲至24歲的人群里大約有85%的人患有某種形式的痤瘡。
總部位于芝加哥的市場(chǎng)研究公司Circana的數(shù)據(jù)顯示,2023年美國(guó)非處方痤瘡治療藥物的銷售總額達(dá)10億美元,幾乎是2019年5.93億美元銷售額的兩倍。美國(guó)皮膚病學(xué)會(huì)指南把過(guò)氧化苯甲酰列為局部痤瘡治療的首選藥物之一。
Valisure公司的總裁大衛(wèi)·萊特指出,發(fā)生污染的原因是過(guò)氧化苯甲酰會(huì)分解并形成苯。
他在接受采訪時(shí)說(shuō):“這一點(diǎn)早已眾所周知。只是需要有人來(lái)檢測(cè)一下?!?/p>
在2023年提交的一份專利申請(qǐng)中,萊特被列為發(fā)明人,該專利涉及一種防止藥品里的過(guò)氧化苯甲酰分解成苯的方法。該實(shí)驗(yàn)室檢測(cè)了其他種類含有不同成分(主要是水楊酸)的祛痘產(chǎn)品,但并未在這些產(chǎn)品中發(fā)現(xiàn)苯含量升高。
Valisure最引人注目的調(diào)查是對(duì)胃灼熱藥物善胃得(Zantac)的調(diào)查:在實(shí)驗(yàn)室發(fā)現(xiàn)該藥物的活性成分雷尼替丁可能形成一種名為NDMA的致癌物幾個(gè)月后,美國(guó)食品與藥品監(jiān)督管理局于2020年將善胃得及其仿制藥從市場(chǎng)上撤下。
美國(guó)食品與藥品監(jiān)督管理局過(guò)去曾經(jīng)對(duì)Valisure的檢測(cè)方法提出過(guò)質(zhì)疑。具體而言,該機(jī)構(gòu)表示,獨(dú)立實(shí)驗(yàn)室應(yīng)該采用與藥品生產(chǎn)商相同的流程,而這種流程往往比Valisure的檢測(cè)方法成本更高。
Valisure堅(jiān)持自己的檢測(cè)方法,并指出自己獲得了國(guó)際標(biāo)準(zhǔn)化組織(International Organization for Standardization)的認(rèn)證。該組織為包括藥品在內(nèi)的各類產(chǎn)品制定了檢測(cè)指南。Valisure在3月6日的一份聲明里表示,該公司對(duì)痤瘡治療產(chǎn)品的研究得出的結(jié)論與對(duì)雷尼替丁產(chǎn)品的調(diào)查研究最為相似。
萊特在聲明中說(shuō):“我們?cè)诜罆袼推渌M(fèi)品里發(fā)現(xiàn)的苯是來(lái)自受污染成分的雜質(zhì);而過(guò)氧化苯甲酰產(chǎn)品中的苯來(lái)自過(guò)氧化苯甲酰本身?!?/p>
2022年,在Valisure先前的研究發(fā)現(xiàn)苯之后,美國(guó)食品與藥品監(jiān)督管理局警告各公司評(píng)估自己產(chǎn)品形成這種化學(xué)物質(zhì)的風(fēng)險(xiǎn)。該機(jī)構(gòu)并不會(huì)定期檢測(cè)其監(jiān)管的產(chǎn)品。
康涅狄格州民主黨眾議員羅莎·德勞羅在一份聲明里說(shuō):“Valisure關(guān)于過(guò)氧化苯甲酰痤瘡治療產(chǎn)品的發(fā)現(xiàn)令人深感不安,并再次強(qiáng)調(diào),一旦我們意識(shí)到處方藥或非處方藥的危險(xiǎn),就必須授權(quán)美國(guó)食品與藥品監(jiān)督管理局立即采取行動(dòng)。過(guò)氧化苯甲酰產(chǎn)品在目前的市場(chǎng)上已經(jīng)達(dá)到飽和,數(shù)百萬(wàn)消費(fèi)者在不知情的情況下使用了這種產(chǎn)品,就增加了他們接觸危及生命的致癌物質(zhì)的機(jī)會(huì)?!?/p>
德勞羅試圖推動(dòng)立法,賦予美國(guó)食品與藥品監(jiān)督管理局召回藥品的權(quán)力,而不是與公司協(xié)商召回藥品(在公司自愿的基礎(chǔ)上)。
Valisure還檢測(cè)了痤瘡治療產(chǎn)品周圍空氣的苯含量,發(fā)現(xiàn)即便是未開封的高倫雅芙產(chǎn)品,在104華氏度(40攝氏度,相當(dāng)于熱水浴的溫度)的環(huán)境中放置近17個(gè)小時(shí)后,也會(huì)釋放出大量的苯。美國(guó)國(guó)家環(huán)境保護(hù)局(Environmental Protection Agency)表示,長(zhǎng)期吸入十億分之0.4濃度的苯,可能會(huì)導(dǎo)致每10萬(wàn)人里多1人罹患癌癥,這也是美國(guó)食品與藥品監(jiān)督管理局采用的風(fēng)險(xiǎn)衡量標(biāo)準(zhǔn)。(財(cái)富中文網(wǎng))
譯者:中慧言-王芳
洗手液被苯污染。防曬霜和干洗發(fā)水也不例外。如今,廣泛使用的消費(fèi)品——痤瘡治療產(chǎn)品也被發(fā)現(xiàn)含有高濃度的致癌化學(xué)物質(zhì)。
3月5日的晚些時(shí)候,一家獨(dú)立檢測(cè)實(shí)驗(yàn)室在向美國(guó)食品與藥品監(jiān)督管理局(US Food and Drug Administration)提交的一份請(qǐng)?jiān)笗蟹Q,包括高倫雅芙(Proactiv)、塔吉特(Target Corp.)旗下的Up & Up和倩碧(Clinique)在內(nèi)的品牌的祛痘產(chǎn)品中含有高濃度的致癌物質(zhì)。該實(shí)驗(yàn)室要求美國(guó)食品與藥品監(jiān)督管理局在監(jiān)管機(jī)構(gòu)調(diào)查期間召回受污染的護(hù)理產(chǎn)品。這些產(chǎn)品都含有活性成分過(guò)氧化苯甲酰。
據(jù)美國(guó)疾病控制與預(yù)防中心(US Centers for Disease Control and Prevention)稱,苯是汽油和煙草煙霧的天然成分,如果吸入高濃度的苯,可能就會(huì)導(dǎo)致白血病。在過(guò)去的三年中,在幾種流行產(chǎn)品里檢測(cè)出苯,這提高了消費(fèi)者對(duì)浴室柜中潛在威脅的認(rèn)識(shí),也引發(fā)了人們質(zhì)疑美國(guó)食品與藥品監(jiān)督管理局對(duì)該行業(yè)監(jiān)管不力。包括強(qiáng)生公司(Johnson & Johnson)、聯(lián)合利華公司(Unilever Plc)和寶潔公司(Procter & Gamble Co.)在內(nèi)的公司已經(jīng)召回了產(chǎn)品。
總部位于美國(guó)康涅狄格州紐黑文的檢測(cè)實(shí)驗(yàn)室Valisure LLC于3月5日提交了請(qǐng)?jiān)笗⒔衣读酥鞍l(fā)現(xiàn)的風(fēng)險(xiǎn)。該公司將自身定位為消費(fèi)者的看門人。Valisure在產(chǎn)品研究方面聲名鵲起,并與包括凱撒醫(yī)療機(jī)構(gòu)(Kaiser Permanente)和美國(guó)國(guó)防部(US Department of Defense)在內(nèi)的大型醫(yī)療保健系統(tǒng)達(dá)成協(xié)議,對(duì)其成員使用的藥物進(jìn)行檢測(cè),以剔除不達(dá)標(biāo)的治療產(chǎn)品。
在痤瘡研究中,Valisure測(cè)試了66種過(guò)氧化苯甲酰產(chǎn)品,包括主要零售商柜臺(tái)或處方銷售的面霜、乳液、凝膠和洗劑。雖然根據(jù)美國(guó)食品與藥品監(jiān)督管理局的指南,允許苯的含量不超過(guò)百萬(wàn)分之二,但Valisure在一些治療產(chǎn)品里發(fā)現(xiàn)的苯含量高達(dá)這一標(biāo)準(zhǔn)的九倍。當(dāng)這些產(chǎn)品在更高的溫度下進(jìn)行測(cè)試時(shí),苯含量明顯升高,測(cè)試的目的是模擬產(chǎn)品隨著時(shí)間的推移可能發(fā)生分解的情況。例如,如果產(chǎn)品存放在蒸汽彌漫的浴室的藥柜中。
在Valisure的穩(wěn)定性測(cè)試中,由Taro Pharmaceutical Industries Ltd.生產(chǎn)的高倫雅芙2.5%過(guò)氧化苯甲酰面霜里的苯含量高達(dá)百萬(wàn)分之1,761,而塔吉特的一款類似面霜的苯含量高達(dá)百萬(wàn)分之1,598,雅詩(shī)蘭黛旗下倩碧的一款面霜的苯含量達(dá)到了百萬(wàn)分之401。利潔時(shí)集團(tuán)(Reckitt Benckiser Group Plc)生產(chǎn)的Clearasil的10%過(guò)氧化苯甲酰面霜最初的測(cè)試結(jié)果剛剛達(dá)到美國(guó)食品與藥品監(jiān)督管理局的限值,但在高溫下暴露兩周多后,苯含量躍升至百萬(wàn)分之308。
利潔時(shí)集團(tuán)在一份聲明中表示:“利潔時(shí)確信,所有Clearasil產(chǎn)品在按照標(biāo)簽說(shuō)明使用和儲(chǔ)存時(shí)都是安全的?!崩麧崟r(shí)稱,公司的首要任務(wù)是保證產(chǎn)品的安全和質(zhì)量。該公司沒有回答是否檢測(cè)了其祛痘霜里的苯含量。
美國(guó)食品與藥品監(jiān)督管理局、Taro Pharmaceuticals和雅詩(shī)蘭黛的代表沒有回應(yīng)置評(píng)請(qǐng)求。塔吉特拒絕置評(píng)。倫敦股市收盤時(shí),利潔時(shí)股價(jià)下跌2%,聯(lián)合利華下跌0.4%;紐約股市收盤時(shí),雅詩(shī)蘭黛下跌1.3%,Taro Pharmaceuticals下跌2.4%。
據(jù)美國(guó)皮膚病學(xué)會(huì)(American Academy of Dermatology)稱,痤瘡是美國(guó)最常見的皮膚病,每年影響多達(dá)5,000萬(wàn)人。在青少年和年輕人中,這一數(shù)字甚至更高:12歲至24歲的人群里大約有85%的人患有某種形式的痤瘡。
總部位于芝加哥的市場(chǎng)研究公司Circana的數(shù)據(jù)顯示,2023年美國(guó)非處方痤瘡治療藥物的銷售總額達(dá)10億美元,幾乎是2019年5.93億美元銷售額的兩倍。美國(guó)皮膚病學(xué)會(huì)指南把過(guò)氧化苯甲酰列為局部痤瘡治療的首選藥物之一。
Valisure公司的總裁大衛(wèi)·萊特指出,發(fā)生污染的原因是過(guò)氧化苯甲酰會(huì)分解并形成苯。
他在接受采訪時(shí)說(shuō):“這一點(diǎn)早已眾所周知。只是需要有人來(lái)檢測(cè)一下?!?/p>
在2023年提交的一份專利申請(qǐng)中,萊特被列為發(fā)明人,該專利涉及一種防止藥品里的過(guò)氧化苯甲酰分解成苯的方法。該實(shí)驗(yàn)室檢測(cè)了其他種類含有不同成分(主要是水楊酸)的祛痘產(chǎn)品,但并未在這些產(chǎn)品中發(fā)現(xiàn)苯含量升高。
Valisure最引人注目的調(diào)查是對(duì)胃灼熱藥物善胃得(Zantac)的調(diào)查:在實(shí)驗(yàn)室發(fā)現(xiàn)該藥物的活性成分雷尼替丁可能形成一種名為NDMA的致癌物幾個(gè)月后,美國(guó)食品與藥品監(jiān)督管理局于2020年將善胃得及其仿制藥從市場(chǎng)上撤下。
美國(guó)食品與藥品監(jiān)督管理局過(guò)去曾經(jīng)對(duì)Valisure的檢測(cè)方法提出過(guò)質(zhì)疑。具體而言,該機(jī)構(gòu)表示,獨(dú)立實(shí)驗(yàn)室應(yīng)該采用與藥品生產(chǎn)商相同的流程,而這種流程往往比Valisure的檢測(cè)方法成本更高。
Valisure堅(jiān)持自己的檢測(cè)方法,并指出自己獲得了國(guó)際標(biāo)準(zhǔn)化組織(International Organization for Standardization)的認(rèn)證。該組織為包括藥品在內(nèi)的各類產(chǎn)品制定了檢測(cè)指南。Valisure在3月6日的一份聲明里表示,該公司對(duì)痤瘡治療產(chǎn)品的研究得出的結(jié)論與對(duì)雷尼替丁產(chǎn)品的調(diào)查研究最為相似。
萊特在聲明中說(shuō):“我們?cè)诜罆袼推渌M(fèi)品里發(fā)現(xiàn)的苯是來(lái)自受污染成分的雜質(zhì);而過(guò)氧化苯甲酰產(chǎn)品中的苯來(lái)自過(guò)氧化苯甲酰本身。”
2022年,在Valisure先前的研究發(fā)現(xiàn)苯之后,美國(guó)食品與藥品監(jiān)督管理局警告各公司評(píng)估自己產(chǎn)品形成這種化學(xué)物質(zhì)的風(fēng)險(xiǎn)。該機(jī)構(gòu)并不會(huì)定期檢測(cè)其監(jiān)管的產(chǎn)品。
康涅狄格州民主黨眾議員羅莎·德勞羅在一份聲明里說(shuō):“Valisure關(guān)于過(guò)氧化苯甲酰痤瘡治療產(chǎn)品的發(fā)現(xiàn)令人深感不安,并再次強(qiáng)調(diào),一旦我們意識(shí)到處方藥或非處方藥的危險(xiǎn),就必須授權(quán)美國(guó)食品與藥品監(jiān)督管理局立即采取行動(dòng)。過(guò)氧化苯甲酰產(chǎn)品在目前的市場(chǎng)上已經(jīng)達(dá)到飽和,數(shù)百萬(wàn)消費(fèi)者在不知情的情況下使用了這種產(chǎn)品,就增加了他們接觸危及生命的致癌物質(zhì)的機(jī)會(huì)?!?/p>
德勞羅試圖推動(dòng)立法,賦予美國(guó)食品與藥品監(jiān)督管理局召回藥品的權(quán)力,而不是與公司協(xié)商召回藥品(在公司自愿的基礎(chǔ)上)。
Valisure還檢測(cè)了痤瘡治療產(chǎn)品周圍空氣的苯含量,發(fā)現(xiàn)即便是未開封的高倫雅芙產(chǎn)品,在104華氏度(40攝氏度,相當(dāng)于熱水浴的溫度)的環(huán)境中放置近17個(gè)小時(shí)后,也會(huì)釋放出大量的苯。美國(guó)國(guó)家環(huán)境保護(hù)局(Environmental Protection Agency)表示,長(zhǎng)期吸入十億分之0.4濃度的苯,可能會(huì)導(dǎo)致每10萬(wàn)人里多1人罹患癌癥,這也是美國(guó)食品與藥品監(jiān)督管理局采用的風(fēng)險(xiǎn)衡量標(biāo)準(zhǔn)。(財(cái)富中文網(wǎng))
譯者:中慧言-王芳
Hand sanitizers were tainted by benzene. Sunscreens and dry shampoos too. Now acne treatments are joining the list of widely used consumer products found to contain high levels of the chemical linked to cancer.
Acne products from brands including Proactiv, Target Corp.’s Up & Up and Clinique have elevated levels of the carcinogen, an independent testing laboratory said in a petition filed with the US Food and Drug Administration late March 5. The lab asked the FDA to recall the affected treatments — all of which contain the active ingredient benzoyl peroxide — while regulators investigate.
Benzene is a natural component of gasoline and tobacco smoke and can cause leukemia in high amounts, according to the US Centers for Disease Control and Prevention. Over the past three years it’s been detected in several popular products, heightening consumers’ awareness of the potential threats in their bathroom cabinets and raising questions about the FDA’s oversight of the industry. Companies including Johnson & Johnson, Unilever Plc and Procter & Gamble Co. have recalled products.
New Haven, Connecticut-based Valisure LLC, the testing laboratory that filed March 5’s petition and uncovered the previous risks, has positioned itself as a gatekeeper for consumers. Valisure gained prominence conducting product research and has deals with large health-care systems, including Kaiser Permanente and the US Department of Defense, to test drugs used by their members and weed out substandard treatments.
For its acne research, Valisure tested 66 benzoyl peroxide products, including creams, lotions, gels and washes available either over the counter from major retailers or via prescription. While FDA guidelines allow up to 2 parts per million of benzene, Valisure found up to nine times that amount in some treatments. Those levels jumped significantly when the products were tested at higher temperatures designed to replicate how they might break down over time, for example if stored in a medicine cabinet in a steamy bathroom.
Proactiv’s 2.5% benzoyl peroxide cream, manufactured by Taro Pharmaceutical Industries Ltd., contained as much as 1,761 parts per million of benzene during Valisure’s stability testing, while a similar cream from Target reached 1,598 parts per million and a treatment from Estee Lauder Cos.’s Clinique hit 401 parts per million. A 10% benzoyl peroxide cream from Reckitt Benckiser Group Plc’s Clearasil initially tested just at the FDA limit, but jumped to 308 parts per million of benzene after being exposed to high temperatures for more than two weeks.
“Reckitt is confident that all Clearasil products, when used and stored as directed on their labels, are safe,” the company said in a statement. The safety and quality of products are its top priority, Reckitt said. It didn’t answer questions about whether it had tested its acne cream for benzene.
Representatives for the FDA, Taro Pharmaceuticals and Estee Lauder didn’t respond to requests for comment. Target declined to comment. Reckitt fell 2% and Unilever dipped 0.4% in London, while Estee Lauder slid 1.3% and Taro tumbled 2.4% at the close in New York.
Acne is the most common skin condition in the U.S., and affects as many as 50 million people each year, according to the American Academy of Dermatology. The numbers are even higher among teenagers and young adults: about 85% of those aged 12 to 24 have some form of the condition.
Sales of over-the-counter US acne treatments totaled $1 billion last year, almost double the $593 million in sales in 2019, data from Chicago-based market research firm Circana showed. The AAD guidelines name benzoyl peroxide as one of its top recommendations for treating acne topically.
Valisure President David Light said the contamination happens because benzoyl peroxide can break down and form benzene.
“This has been well known for a long time,” he said in an interview. “All that was needed was for someone to check on it.”
Light is listed as an inventor on a patent filed last year for a method to prevent benzoyl peroxide from breaking down into benzene in drug products. The lab tested other kinds of acne products with different ingredients, mainly salicylic acid, and did not find elevated benzene levels in those.
Valisure’s most high-profile investigation was into heartburn drug Zantac, which the FDA pulled from the market along with generic versions in 2020, months after the lab discovered the drug’s active ingredient — ranitidine — could form a probable carcinogen called NDMA.
The FDA has questioned Valisure’s testing methods in the past. Specifically, the agency has said the independent lab should follow the same process that drug manufacturers use, which tends to be costlier than the way that Valisure tests.
Valisure stands behind its testing methods and points to its certification from the International Organization for Standardization, which sets testing guidelines for all kinds of products including drugs. In a statement on March 6, Valisure said the results from its research on acne treatments were most similar to its investigation into those ranitidine products.
“The benzene we found in sunscreens and other consumer products were impurities that came from contaminated ingredients; however, the benzene in benzoyl peroxide products is coming from the benzoyl peroxide itself,” Light said in the statement.
In 2022, following Valisure’s previous benzene findings, the FDA warned companies that they should assess the risk of the chemical forming in their own products. The agency doesn’t regularly test products it oversees.
“The discovery made by Valisure regarding benzoyl peroxide acne treatment products is deeply troubling and gives renewed importance to the need to empower the FDA to immediately act once we are made aware of the dangers of prescription or over-the-counter drugs,” US Representative Rosa DeLauro, a Connecticut Democrat, said in a statement. “Benzoyl peroxide products saturate the current market and millions of consumers are unknowingly using a product that increases their exposure to life-threatening carcinogens.”
DeLauro has attempted to push legislation that would give the FDA the authority to recall drugs rather than negotiate with companies to do so on a voluntary basis.
Valisure’s testing also examined benzene in the air surrounding acne treatments and found that even an unopened Proactiv product leaked high levels when kept at 104 degrees Fahrenheit, the temperature of a hot shower, for almost 17 hours. The Environmental Protection Agency has said inhaling benzene at levels of 0.4 parts per billion chronically over a lifetime could result in one additional cancer per 100,000 people, a measure of risk the FDA also uses.